Irinotecan plus fluorouracil/leucovorin (IFL) verus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803)

Reviewer: Neha Vapiwala, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 6 de junio del 2004

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

Addition of Oxaliplatin Ups Survival in Stage II/III Colon CA

Aug 30, 2011

FULV plus oxaliplatin ups disease-free survival; overall survival improves only in patients <70 years

FOLFOXIRI + Bevacizumab Ups Outcome in Metastatic CRC

Oct 24, 2014

Findings show benefits compared with FOLFIRI for patients with untreated metastatic disease

Bevacizumab Doesn't Prolong Survival in Stage II-III Colon CA

Dec 12, 2012

One-year of adjuvant bevacizumab + FOLFOX6 has no benefit on disease-free, overall survival

From the National Cancer Institute